Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults
Status:
COMPLETED
Trial end date:
2025-05-14
Target enrollment:
Participant gender:
Summary
The study included three phases: the treatment introduction period (4-7 days before randomization), the treatment period (14 days after randomization) and the follow-up period (7 days after the last dose). Eligible participants in this study entered the 4-7 day treatment introduction period. After completing the treatment introduction period, patients who did not meet the random exclusion criteria of this study were randomly assigned to one of the 4 dose cohorts in a 1:1:1:1 ratio, with 80 patients planned to be enrolled in each cohort, and then randomly assigned to receive the investigational product or placebo in the cohort at a 4:1 ratio, for a total of 320 patients. Participants were stratified by prior Drug therapy for Rhinitis allergic. Ultimately, the proportion of patients receiving 200 g BID, 400 g BID, 400 g QD, 800 g QD and placebo was 1:1:1:1:1 (64 patients in each group).